Get the Stockscreener App
5.91
0.17%
-0.010
After Hours:
5.91
Myriad Genetics Inc stock is traded at $5.91, with a volume of 630.68K.
It is down -0.17% in the last 24 hours and up +30.18% over the past month.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.
See More
Previous Close:
$5.92
Open:
$5.84
24h Volume:
630.68K
Relative Volume:
0.40
Market Cap:
$558.19M
Revenue:
$829.00M
Net Income/Loss:
$-399.90M
P/E Ratio:
-1.3694
EPS:
-4.3159
Net Cash Flow:
$-23.20M
1W Performance:
-2.15%
1M Performance:
+30.18%
6M Performance:
+1.20%
1Y Performance:
+32.81%
1-Day Range:
$5.835
$5.985
1-Week Range:
$5.83
$6.43
52-Week Range:
$3.53
$8.59
Myriad Genetics Inc Stock (MYGN) Company Profile
Name
Myriad Genetics Inc
Sector
Industry
Phone
801-584-3600
Address
322 NORTH 2200 WEST, SALT LAKE CITY, UT
Compare MYGN vs TMO, DHR, IDXX, NTRA, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MYGN
Myriad Genetics Inc
|
5.91 | 559.13M | 829.00M | -399.90M | -23.20M | -4.3159 |
TMO
Thermo Fisher Scientific Inc
|
523.46 | 195.56B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
179.01 | 142.34B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
552.46 | 44.48B | 4.45B | 1.10B | 1.06B | 13.59 |
NTRA
Natera Inc
|
267.18 | 37.61B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
132.86 | 36.79B | 7.23B | 1.41B | 1.09B | 4.979 |
Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-21-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| May-08-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| May-07-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-09-25 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Feb-12-25 | Initiated | Craig Hallum | Buy |
| Dec-10-24 | Initiated | UBS | Neutral |
| Dec-09-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Sep-19-24 | Initiated | Morgan Stanley | Equal-Weight |
| Aug-28-24 | Initiated | Wells Fargo | Overweight |
| Jun-27-24 | Initiated | Scotiabank | Sector Outperform |
| Jun-03-24 | Resumed | Jefferies | Underperform |
| May-08-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Dec-21-23 | Resumed | Piper Sandler | Neutral |
| Dec-19-23 | Initiated | Wells Fargo | Equal Weight |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Jul-05-23 | Resumed | JP Morgan | Underweight |
| May-23-23 | Upgrade | Goldman | Sell → Buy |
| Jan-18-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-06-22 | Initiated | Stephens | Equal-Weight |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| Jun-03-21 | Initiated | Goldman | Sell |
| Sep-26-19 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Aug-14-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Aug-02-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Aug-01-19 | Upgrade | Barclays | Underweight → Equal Weight |
| Jul-29-19 | Downgrade | Needham | Strong Buy → Hold |
| Jul-09-19 | Downgrade | Cowen | Outperform → Market Perform |
| Mar-12-19 | Reiterated | Needham | Strong Buy |
| Jan-03-19 | Initiated | Needham | Strong Buy |
| Nov-30-18 | Upgrade | Goldman | Sell → Neutral |
| Oct-10-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jul-11-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-21-18 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jan-29-18 | Initiated | Goldman | Sell |
| Jan-22-18 | Reiterated | Barclays | Equal Weight |
| Jan-05-18 | Initiated | BTIG Research | Buy |
| Oct-02-17 | Resumed | Leerink Partners | Mkt Perform |
| Aug-09-17 | Reiterated | Barclays | Equal Weight |
| Feb-08-17 | Upgrade | Ladenburg Thalmann | Sell → Neutral |
| Jan-18-17 | Initiated | Deutsche Bank | Sell |
| Oct-10-16 | Downgrade | Ladenburg Thalmann | Neutral → Sell |
View All
Myriad Genetics Inc Stock (MYGN) Latest News
Myriad Genetics Launches New Four-in-One Prenatal Genetic Screen - Clinical Lab Products
Myriad Genetics launches prenatal genetic screening test - Investing.com
Myriad Genetics launches prenatal genetic screening test By Investing.com - Investing.com Canada
Myriad's one-draw test runs four prenatal screens at 8 weeks - Stock Titan
Burning Rock and Myriad Announce Global Strategic Technology Licensing Partnership to Expand HRD Testing Worldwide - EIN News
AWHL vs. MYGN: Which women's health diagnostics stock is better now? - MSN
ETFs Investing in Myriad Genetics, Inc. Stocks - TradingView
AWHL vs. MYGN: Which Women's Health Diagnostics Stock is Better Now? - The Globe and Mail
MYGN Stock Price, Quote & Chart - ChartMill
Myriad Genetics reports FirstGene prenatal screen achieves over 98 percent sensitivity and 99 percent specificity - Traders Union
Is This the Right Time to Hold MYGN Stock in Your Portfolio? - Yahoo Finance
Is MYGN Stock a Buy at 0.4x Sales? What Investors Should Weigh - qz.com
BofA Securities Maintains Myriad Genetics(MYGN.US) With Sell Rating, Announces Target Price $4 - Moomoo
Myriad Genetics (MYGN) Q4 2024 earnings summary - Quartr
Myriad Genetics (MYGN) Proxy filing Summary - Quartr
AI upgrade boosts Prolaris Test predictive power at Myriad Genetics - Traders Union
(MYGN) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Myriad Genetics (MYGN) Surges 3.5%: Approaching Resistance at $6.51ADD Alert - dars.gov.et
Myriad Genetics Q1 2026 Earnings: EPS Miss Clouds Diagnostic Growth OutlookGross Profit Margin - dars.gov.et
Meta-analysis confirms Myriad's Prolaris test e... - Pluang
New Large-Scale Meta-Analysis Demonstrates Strong Prognostic Performance of Myriad's Prolaris Biopsy Test in Localized Prostate Cancer - 富途牛牛
New Large-Scale Meta-Analysis Demonstrates Strong - GlobeNewswire
SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF MARK CAPONE TO ITS BOARD OF DIRECTORS - BioSpace
Sera Prognostics adds former Myriad Genetics CEO to board By Investing.com - Investing.com South Africa
MYGNMyriad Genetics Inc Latest SEC Filings - Finviz
Sera Prognostics adds former Myriad Genetics CEO to board - Investing.com
Sera Prognostics adds former Myriad CEO Mark Capone to board - Stock Titan
Spotting Winners: Myriad Genetics (NASDAQ:MYGN) And Therapeutics Stocks In Q1 - Yahoo Finance
Myriad (MYGN) Soars 8.3%: Is Further Upside Left in the Stock? - Yahoo Finance
(MYGN) Risk Channels and Responsive Allocation - Stock Traders Daily
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Price to sales forward of Myriad Genetics, Inc. – NASDAQ:MYGN - TradingView
Price to book forward of Myriad Genetics, Inc. – NASDAQ:MYGN - TradingView
Myriad Genetics, Inc. Actuals & Estimates (NASDAQ:MYGN) - TradingView
897518 Forecast — Price Target — Prediction for 2027 - TradingView
Price to earnings forward of Myriad Genetics, Inc. – LS:897518 - TradingView
Price to sales forward of Myriad Genetics, Inc. – LS:897518 - TradingView
Enterprise value to revenue forward of Myriad Genetics, Inc. – NASDAQ:MYGN - TradingView
Enterprise value to revenue forward of Myriad Genetics, Inc. – LS:897518 - TradingView
MYGN Forecast — Price Target — Prediction for 2027 - TradingView
Myriad Genetics, Inc. Actuals & Estimates (FWB:MYD) - TradingView
Myriad Genetics expands Precise MRD availability to boost precision medicine adoption - Traders Union
Myriad Genetics clears analyst hurdle, shares steady on NASDAQ - Ad-hoc-news.de
MYD Forecast — Price Target — Prediction for 2027 - TradingView
Why Is Myriad Genetics (MYGN) Stock Rocketing Higher Today - Yahoo Finance
Myriad Genetics Expands Availability of Precise MRD™ for Colorectal, Renal and Breast Cancers, Supported by New Publication - Sahm
Director at Myriad Genetics (MYGN) reports 195,507-share Common Stock stake - Stock Titan
Myriad Genetics expands cancer detection test availability By Investing.com - Investing.com Australia
Form 8K Myriad Genetics Inc For: 23 June By Investing.com - Investing.com Australia
MYGN PE Ratio & Valuation, Is MYGN Overvalued - Intellectia AI
Myriad Genetics expands cancer detection test availability - Investing.com
Myriad Genetics Inc Stock (MYGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
1.92%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):